Foresite Capital logo

Foresite Capital

Crunchbase
Crunchbase

Deals on record

6

Common Fundraising Type

Series B

Pleno logo
Pleno

Clinical diagnostics

Medical Excellence Capital logo
Foresite Capital logo
Deerfield Management logo

Pleno, Inc. is a clinical and multi-omics diagnostics company focused on revolutionizing biological target detection with its RAPTOR™ multi-omic instrument platform.

Series B
$25M
12/12/2024
Article
Sollis Health logo
Sollis Health

Concierge medical services

Sollis Health provides 24/7 concierge medical services with a focus on high-touch member experiences and proprietary technology.

Series B
$33M
12/05/2024
Article
Avenzo Therapeutics logo
Avenzo Therapeutics

Biotechnology

TF Capital logo
Surveyor Capital logo
SR One logo
Sofinnova Investments logo
Sands Capital logo
Quan Capital logo
OrbiMed logo
New Enterprise Associates logo

Avenzo Therapeutics is a biotechnology company developing oncology therapies, including a CDK2 inhibitor for advanced solid tumors and HR+/HER2-negative metastatic breast cancer.

Series A
Undisclosed
11/19/2024
Article
Seaport Therapeutics logo
Seaport Therapeutics

Neuropsychiatric

General Atlantic logo
T. Rowe Price Associates logo
Sofinnova Investments logo
Third Rock Ventures logo
PureTech Health logo
Invus logo
Goldman Sachs Alternatives logo
Foresite Capital logo

Seaport Therapeutics develops neuropsychiatric medicines using its Glyph technology platform to enhance oral bioavailability and reduce side effects, with a focus on treating depression, anxiety, and other disorders.

Series B
$225M
10/22/2024
Article
Candid Therapeutics logo
Candid Therapeutics

Biotechnology

Venrock Healthcare Capital Partners logo
Vida Ventures logo
TCGX logo
Third Rock Ventures logo
Soleus Capital logo
Samsara BioCapital logo
Redmile Group logo
Polaris Innovation Fund logo

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

Equity
$370M
09/09/2024
Article

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Series C
$101M
12/05/2023
Article